ETOPOSIDE INJECTION DIN 02080036
Health Canada record
| Active ingredient(s) | ETOPOSIDE 20 MG |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L01CB01 ETOPOSIDE |
| Original market date | 31-Dec-1994 |
| Current status date | 12-Apr-2014 |
| Source | Health Canada DPD |
Establishment licence of the holder
Teva Canada Limited — licence 101810, currently licensed, last inspection rating C (2025-03-04).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ETOPOSIDE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02552671 | ETOPOSIDE INJECTION | HIKMA CANADA LIMITED | Solution | ETOPOSIDE 20 MG | Marketed |
| 00616192 | VEPESID | CHEPLAPHARM ARZNEIMITTEL GMBH | Capsule | ETOPOSIDE 50 MG | Marketed |
| 02237872 | DOM-ETOPOSIDE | DOMINION PHARMACAL | Liquid | ETOPOSIDE 20 MG | Cancelled Pre Market |
| 02237428 | EPOSIN | PHARMACHEMIE B.V. | Liquid | ETOPOSIDE 20 MG | Cancelled Pre Market |
| 02237873 | ETOPOSIDE | PHARMEL INC | Liquid | ETOPOSIDE 20 MG | Cancelled Pre Market |
| 02227509 | ETOPOSIDE - LIQ IV 20MG/ML | BDH INC. | Liquid | ETOPOSIDE 20 MG | Cancelled Post Market |
| 02239961 | ETOPOSIDE INJECTION | FRESENIUS KABI CANADA LTD | Liquid | ETOPOSIDE 20 MG | Dormant |
| 02380935 | ETOPOSIDE INJECTION USP | SANDOZ CANADA INCORPORATED | Solution | ETOPOSIDE 20 MG | Cancelled Post Market |
| 02241182 | ETOPOSIDE INJECTION, USP | HOSPIRA HEALTHCARE ULC | Solution | ETOPOSIDE 20 MG | Cancelled Post Market |
| 02422530 | ETOPOSIDE INJECTION, USP | STRIDES PHARMA CANADA INC | Solution | ETOPOSIDE 20 MG | Dormant |
| 02237871 | PMS-ETOPOSIDE | PHARMASCIENCE INC | Liquid | ETOPOSIDE 20 MG | Cancelled Pre Market |
| 00523410 | VEPESID INJ 20MG/ML | BRISTOL LABS DIVISION OF BRISTOL-MYERS SQUIBB | Liquid | ETOPOSIDE 20 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 15489 | 2014-04-11 | New Drug Submission (NDS) | MANUFACTURER NAME CHANGE |
| 5786 | 1994-03-07 | New Drug Submission (NDS) |
International API supply for ETOPOSIDE
6 valid EDQM Certificates of Suitability from 6 holders. 7 active FDA Drug Master Files.
Special Access Programme
This molecule appears on Health Canada's list of drugs most often requested through the Special Access Programme.
Request a quote for ETOPOSIDE INJECTION